Growth Hormone Administration and the Human Immune System

Healthy Volunteers Clinical Trial

Official title:

Growth Hormone Administration and the Human Immune System

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00663611
• Other study ID #: 999907260
• Secondary ID: 07-AG-N260
• Status: Completed
• Phase: Phase 1
• Start date: October 19, 2006
• Est. completion date: October 6, 2014

Study information

• Verified date: August 24, 2023
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background:

• In elderly individuals, an age-associated decline in the immune system s ability to function is believed to contribute to increased incidence of infection, autoimmune disorders, and cancer. This decline in immune system function may be related to the decline in the body s production of growth hormone, which helps regulate human development and may contribute to the health of the immune system. Researchers are interested in studying whether growth hormone, given as an infusion over time, can improve the function of the immune system and other body systems associated with good health.

Objectives:

• To study the effects of growth hormone administration on the immune systems of healthy men.

Eligibility:

• Healthy men between 25 and 50 years of age.

Design:

• This protocol will involve three separate studies: Study I, Study IB, and Study II. Participants in Study I and Study IB may participate in Study II as directed by the researchers.

• Participants will be screened with a full medical history and physical examination, and will provide blood, urine, and stool samples; have a glucose tolerance test; and have other tests as required by the researchers.

• Participants will have an infusion pump with a small catheter inserted beneath the skin to administer the study chemicals (either growth hormone or placebo).

• Study I and Study IB participants will receive pulses of growth hormone through the infusion pump at regular intervals to monitor the body s response to the hormone. Study IB participants will receive a higher dose of growth hormone than Study I participants.

• Throughout the study period, all participants will have frequent blood and urine tests, as well as tests of glucose tolerance and metabolism, imaging studies, and other tests as required by the researchers.

• Study II participants will be divided into two groups. The first group will receive pulses of either growth hormone or placebo infusion at intervals throughout the day for 4 weeks, followed by an 8-week period without infusions. The second group will receive conventional once-a-day infusion of growth hormone or placebo for 4 weeks, followed by an 8-week period without infusions.

• Throughout the study period, all participants will have frequent blood and urine tests, as well as tests of glucose tolerance and metabolism, imaging studies, and other tests as required by the researchers.

Description:

Objectives and Specific Aims:

We plan to investigate whether growth hormone, administered in a physiological or pulsatile fashion, can elicit relevant changes in the human immune system while at the same time associated with no change or even an improvement in the metabolic profiles such as insulin sensitivity.

Experimental Design and Methods:

Thirty-eight healthy men, age 25-50, will be recruited for this study. There are three parts to this study: Study I, Study IB and Study II. Study I and IB each involve six subjects and are designed to test the hypothesis that pulsatile subcutaneous infusion of GH via a subcutaneous infusion pump will yield a reasonable pulsatile GH pattern. The dose of GH used in Study IB will be three-fold higher that that in Study I. Study I and IB will be done first before proceeding to Study II.

Study II is a randomized, double-blinded, placebo-controlled 12-week study involving 26 subjects divided into 2 groups: Group A and Group B. Group A will involve 13 subjects receiving pulsatile GH or placebo infusion for 4 weeks with 8-week washout after intervention. Group B will involve 13 subjects receiving conventional once a day subcutaneous infusion of GH or placebo for 4 weeks with 8-week washout after intervention.

Medical Relevance and Expected Outcome:

This study will ascertain the significance of the effect of pulsatile growth hormone administration on the human immune system and metabolic profile.

Other known NCT identifiers

• NCT00663676

Recruitment information / eligibility

• Status: Completed
• Enrollment: 66
• Est. completion date: October 6, 2014
• Est. primary completion date: October 6, 2014
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 25 Years to 50 Years

Eligibility

• INCLUSION CRITERIA:

1. Healthy men only

2. Age 25-50

3. Screening laboratory evaluations with no clinically significant abnormal results (minor deviations from normal lab results will be at the discretion of the principal investigator):

1. fasting comprehensive metabolic panel

2. complete blood count with differential and platelets

3. 75-gram oral glucose tolerance test (OGTT)

• fasting plasma glucose (FPG) < 100 mg/dL

• 2-hr OGTT < 140 mg/dL

4. Insulin-like growth factor-I (IGF-I)

5. thyroid function test (TSH, free T3, free T4)

6. fasting lipid profile

4. BMI < 30

5. Have NOT participated in another clinical trial involving any pharmacologic agents within the past 60 days

6. Able to complete an inform consent

7. Agree to not participate in other clinical trials within the study period

EXCLUSION CRITERIA:

1. Women

2. FPG 100 mg/dL or 2-hour OGTT 140 mg/dL

3. Abnormal electrocardiogram (EKG) suggesting possible underlying cardiac conditions that, in the opinion of the investigator(s), may cause participation of the subject in the study unsafe

4. Positive stool guaiac

5. Evidence of illicit drug use

6. History of smoking any tobacco products within one year prior to screening

7. Alcohol intake > 30 grams (drink more than 2 beers per day OR equivalent amount of alcohol)

8. History of Human Immunodeficiency Virus (HIV) infection

9. History of active or chronic Hepatitis B and/or C infection

10. History of malignancy

11. History of coronary disease

12. History of seizures or other neurologic diseases

13. History of liver or renal diseases

14. History of gastrointestinal or endocrine disorders

15. History of glucocorticoid use (over one month) or other immunosuppressive agents (any)

16. unable to undergo a magnetic resonance imaging (MRI) procedure

17. Any medical history that, in the opinion of the investigator(s), will make participation of the subject in the study unsafe

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• Norditropin
Norditropin (somatropin, rDNA origin) is a polypeptide hormone of recombinant DNA origin. The amino acid sequence of the product is identical to that of the human growth hormone of pituitary origin.
• Placebo
0.9% normal saline

Locations

Country	Name	City	State
United States	National Institute of Aging, Clinical Research Unit	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Bar-Dayan Y, Small M. Effect of bovine growth hormone administration on the pattern of thymic involution in mice. Thymus. 1994;23(2):95-101. — View Citation

Murphy WJ, Durum SK, Longo DL. Role of neuroendocrine hormones in murine T cell development. Growth hormone exerts thymopoietic effects in vivo. J Immunol. 1992 Dec 15;149(12):3851-7. — View Citation

Napolitano LA, Lo JC, Gotway MB, Mulligan K, Barbour JD, Schmidt D, Grant RM, Halvorsen RA, Schambelan M, McCune JM. Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS. 2002 May 24;16(8):1103-11. doi: 10.1097/00002030-200205240-00003. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	GH administration may elicit clinical significant and relevant changes in the human immune system		4 weeks